Kisqali
KISQALI (ribociclib) is a pharmaceutical product used in combination with an AI for HR+, HER2- early breast cancer and with hormone therapy for HR+, HER2- metastatic breast cancer.
Last updated September 11, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
KISQALI (ribociclib) is described on its official site as a treatment that, combined with an AI, can help people with HR+, HER2- stage 2 or 3 early breast cancer (eBC) with a high risk of coming back, and that, combined with hormone therapy, can help people with HR+, HER2- metastatic breast cancer (mBC). The site states KISQALI is not approved for use with tamoxifen and lists serious side effects including lung problems, severe skin reactions, and heart rhythm problems (QT prolongation). Novartis Patient Support is referenced as a support program for people taking KISQALI.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/kisqali · Editorial policy · How profiles are compiled